The Food and Drug Administration (FDA) has recently included a black box warning on fibromyalgia-like symptoms with fluoroquinolones (FQs) but no large epidemiologic study is to date available. We undertook a case-control study using a random sample of 9 053 240 subjects obtained from the PharMetrics Plus health claims database in the United States. Cases received at least two fibromyalgia diagnoses coded by a rheumatologist matched to ten randomly selected controls. After identifying 5148 cases of fibromyalgia and 51 480 controls, the adjusted rate ratio (RR) of fibromyalgia for use of any fluoroquinolones, amoxicillin and azithromycin were 1.63 (95% CI: 1.41-1.87), 1.64 (95% CI: 1.46-1.85) and 1.68 (95% CI, 1.49-1.89), respectively. The adjusted RR for any use of FQ compared to any use of amoxicillin or azithromycin was 0.99 (95% CI: 0.83-1.18) and azithromycin is 0.97 (95%CI: 0.82-1.16), respectively. The risk of fibromyalgia with FQs is similar to that with amoxicillin and azithromycin.
Introduction
Oral fluoroquinolones (FQs) are one of the most prescribed classes of antibiotics in the world. Recently, the Food and Drug Administration (FDA) issued a black box warning on FQs, which included debilitating musculoskeletal-relatednerves, and fibromyalgia [1] . Case series have described patients on FQs who experienced a multitude of adverse events while on FQs, including fibromyalgia-like disabling symptoms of fatigue, severe muscle weakness and atrophy [2] . Recent studies have shown that mitochondrial dysfunction may underlie and connect these different conditions, in particular multisymptomatic disorders [2] . Mitochondrial dysfunction and free radical formation may cause oxidative stress, and oxidative stress in turn increases mitochondrial damage [2] .
Previous studies have found an elevated risk with FQs and tendon rupture [3] , peripheral neuropathy [4] and carpal tunnel syndrome [5] . To date, no epidemiologic study has assessed the risk of FQs with disabling musculoskeletal outcomes. Moreover, given that respiratory infections for which FQs are prescribed may also lead to fibromyalgia [6] , it is unclear whether the reported musculoskeletalrelated adverse events with FQs are due to confounding by infection or the effect of FQs. Given that the FQ-related adverse events resemble fibromyalgia, we sought to examine the risk of fibromyalgia with FQs by performing a large epidemiologic study.
Methods

Data sources and study design
We used a random sample of PharMetrics Plus, a large health claims database in the United States, as the main data source for this study. The database captures health-related claims for over 150 million unique enrolees, which includes fully adjudicated pharmacy and medical claims. All medical diagnoses are captured through international classification of diseases, ninth and tenth editions (ICD-9 and 10). All outpatient prescription drugs are captured, which includes information on drug name, dose quantity dispensed and day supply. The database is a reasonable representation of all geographic areas of the United States [7] . The study used a case-control design using a random sample of 9 053 240 subjects from 2006 to 2016. A case-control design was chosen as it only uses a sample of the population (as controls) for the estimation of the rate ratio (RR), mitigating complexities that may arise from a cohort design which will use a large sample of the greater than 9 million subject cohort. Ethics approval was obtained from the University of British Columbia clinical ethics board. No patient consent was necessary as this study did not use real patient data.
Case and control selection
From the base cohort we excluded conditions strongly correlated with fibromyalgia and FQ use including hepatitis B and C, infectious mononucleosis, myopathies, rheumatoid arthritis and lupus erythematosus ( Figure 1 ). Cases were identified as those with the first ICD-9 or 10 code for fibromyalgia coded by a rheumatologist. Cases had to have received at least an additional code after the first code. The date of the first code was deemed the index date. Subjects with previous fibromyalgia codes by any other physician type were excluded. For each case, ten controls without diagnosis of fibromyalgia were matched to a case by density based-sampling, which ensured that cases were at risk of developing fibromyalgia where each control could become a future case, generating odds ratios that closely resemble a rate ratio from a cohort study [8] . Cases were matched to controls by calendar time, age and gender. Additionally, we excluded conditions that mimic fibromyalgia. We ensured the cases and controls had at least one year look back period to allow for the ascertainment of the study drugs in the year prior to the event date.
Exposure definition and statistical analysis
We identified all FQ prescriptions in the year prior to the index date. To control for disease latency and reverse causality, the first 60 days prior to the index date (Days 0-60) were disregarded. Exposure was defined as use of at least one FQ prescription from Day 61-365 prior to the index date. To control for possible confounding by viral or bacterial infection, we also examined the risk of fibromyalgia with two different mutually exclusive antibiotics, amoxicillin and azithromycin, which are chemically unrelated to FQs. FQs were not exposed to amoxicillin or azithromycin during the exposure period.
These two antibiotics were chosen as they have a different mechanism of action, with amoxicillin being widely used in the treatment of bacterial infections and azithromycin generally being used for more severe respiratory infections due to its wider spectrum of bacterial coverage and high tissue penetration. The comparator group were those not taking any of the three study antibiotics. Demographics between cases and controls were assessed using student t-test or chi-square test. Conditional logistic regression was used to adjust for previous diagnosis of hypothyroidism, polyarthritis rheumatica and Lyme disease. 
Results
We identified 5148 cases and 51 480 controls ( Table 1) . As fibromyalgia affects mostly females, 87% of the cases were women ( Table 1 ). The adjusted rate ratio (RRs) for use of any FQs, amoxicillin and azithromycin were 1.63 (95% CI: 1.41-1.87), 1.64 (95% CI: 1.46-1.85) and 1.68 (95% CI: 1.49-1.89) ( Table 2 ). The RRs for patients who took one or more than one prescription were comparable among the three antibiotics ( Table 2 ). The RR for any use of FQ compared to any use of amoxicillin or azithromycin was 0.99 (95% CI: 0.83-1.18) and azithromycin was 0.97 (95% CI: 0.82-1.16) respectively.
Discussion
The results of our study indicated that the risk of fibromyalgia with FQs is similar to amoxicillin and azithromycin. These data indicate that the possible association between FQs and fibromyalgia is possibly due to the viral or bacterial infection for which they are prescribed. This is corroborated by a number of studies that have shown that fibromyalgia might be triggered by an infectious process [6] . Our data is corroborated by inclusion of azithromycin, an antibiotic generally prescribed for more severe respiratory community-acquired infections. Azithromycin has high tissue penetration and has also been shown to affect mammalian mitochondria [9] similar to fluoroquinolones [10] .
A number of postulated mechanisms might explain the elevated risk of fibromyalgia with the three antibiotics. First, studies have shown that fibromyalgia may be triggered by an immune response secondary to an infectious process [6, 11] . This may be due to the activation of the immune system leading to increased serum levels of cytokines (IL-2, IL-8 and IL-2r) in addition to lymphocytes expressing opiate receptors that respond to substance P, a primary pain modulator [12] . Moreover, cross-sectional studies have shown that 20% of patients with fibromyalgia have reported a previous infection and another study reported that 50% of patients reported 'flu like symptoms' preceding fibromyalgia diagnosis [6, 13] . Second, diseases that are a result of disrupted gut microflora such as irritable bowel syndrome have been found to be highly co-morbid with fibromyalgia, reaching rates as high as 81% [14, 15] . Recent work has also shown that antibiotics disrupt gut microflora as they kill off both commensal and pathogenic bacteria [16] . Therefore, it is possible that gut dysbiosis may play a role in fibromyalgia development. If true, microflora dysbiosis may further exacerbate the immunocompromised state of fibromyalgia patients, as commensal Table 2 Crude and adjusted rate ratios of fibromyalgia and intake of fluoroquinolones, amoxicillin or azithromycin antibiotics bacterial are critical to maintaining a healthy immune response [17] . The strength of our study is the large sample size and careful consideration for disease latency and reverse causality. As with all epidemiologic studies and the use of health claims data, our study has limitations. We did not have access to patient medical records. We also did not have information on family history of fibromyalgia or alcohol use, although these variables, being risk factors for and not confounders of, would be unlikely to bias the study results. It is possible that some of the cases which may have been coded for fibromyalgia may have in fact had a viral myopathy [18] . However, this scenario is unlikely as symptoms of viral infectious would usually manifest in the first 60 days of using an FQ, which is the period that we excluded in the study.
In summary, despite the case reports of fibromyalgia and FQ use in both the literature and various drug regulatory agencies, risk seems to be similar with amoxicillin and azithromycin. Risk might therefore be due to possible infection that triggered fibromyalgia symptoms.
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